Multiple Myeloma Drugs Market: Growth Opportunities led by Abbott Laboratories and AbbVie Inc. - Technavio

·17 min read

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- The multiple myeloma drugs market size is estimated to grow by USD 6,419.94 million during 2021-2026, at a CAGR of 5.9%. The growth of the market will be driven by the growing incidence of multiple myeloma. Furthermore, the emergence of nanomedicine platforms is expected to boost market growth.

Technavio has announced its latest market research report titled Global Multiple Myeloma Drugs Market 2023-2027
Technavio has announced its latest market research report titled Global Multiple Myeloma Drugs Market 2023-2027

The report extensively covers the multiple myeloma drugs market segmentation by therapy (targeted therapy, biologic therapy, chemotherapy, and others), distribution channel (hospital pharmacy, retail pharmacy, and e-pharmacy), and geography (North America, Europe, Asia, and Rest of the World (ROW). Request A Free Sample Report

Multiple Myeloma Drugs Market - Vendors

The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market.

  • Amgen Inc.

  • AbbVie Inc.

  • Amgen Inc.

  • AstraZeneca Plc

  • Bristol Myers Squibb Co.

  • Cipla Ltd.

  • Daiichi Sankyo Co. Ltd.

  • Eli Lilly and Co.

  • F. Hoffmann La Roche Ltd.

  • Fresenius SE and Co. KGaA

  • GlaxoSmithKline Plc

  • Johnson and Johnson

  • Merck and Co. Inc.

  • Novartis AG

Product Insights and News

  • Amgen Inc.: The company offers multiple myeloma drugs such as Kyprolis.

  • AbbVie Inc.: The company offers multiple myeloma drugs such as Vysis 13q34 SpectrumGreen FISH Probe Kit.

  • Amgen Inc.: The company offers multiple myeloma drugs such as Kyprolis.

For detailed insights about product offerings and the growth strategies adopted by vendors, buy the report.

Multiple Myeloma Drugs Market - Geographical Landscape

North America is estimated to account for 36% of the market's growth during the forecast period. The growing prevalence of various cancer indications, including multiple myeloma and non-Hodgkin's lymphoma is driving the growth of the regional market. The market in North America is further benefitted from the availability and high sales of approved multiple myeloma drugs. The patent expiry of a major drug brand has resulted in the development of generic versions of the drug by various large- and mid-sized pharmaceutical vendors in the region. This is contributing to the growth of the multiple myeloma drugs market in North America.

 Multiple Myeloma Drugs Market - Market Segmentation

The targeted therapy segment is estimated to contribute significantly to the global market's growth during the forecast period. The increasing demand for targeted therapies is driven by the efficacy of the therapy in blocking the action of a substance in myeloma cells that disrupt proteins. This action helps in killing the myeloma cells. Also, the increasing number of drug approvals for the treatment of multiple myeloma is fueling the growth of the segment.

Additionally, recent approvals are showing impressive sales growth, which represents the continued strong adoption of proteasome inhibitors for the treatment of multiple myeloma. - Download a free sample report

What are the key data covered in this multiple myeloma drugs market report?

  • CAGR of the market during the forecast period

  • Detailed information on factors that will drive the growth of the multiple myeloma drugs market between 2023 and 2027

  • Precise estimation of the size of the multiple myeloma drugs market size and its contribution of the market in focus to the parent market

  • Accurate predictions about upcoming trends and changes in consumer behavior

  • Growth of the multiple myeloma drugs market industry across APAC, North America, Europe, Middle East and Africa, and South America

  • Thorough analysis of the market's competitive landscape and detailed information about vendors

  • Comprehensive analysis of factors that will challenge the growth of multiple myeloma drugs market vendors

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

Related Reports:

Compounding Pharmacy Market by Product and Geography - Forecast and Analysis 2022-2026: The compounding pharmacy market share is expected to increase by USD 1.5 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 2.15%.

Proteasome Inhibitors Market by Product and Geography - Forecast and Analysis 2022-2026: According to Technavio's analyst, the proteasome inhibitors market size is expected to be valued at USD 2.20 billion by 2026 with a CAGR of 7.4%.

Multiple Myeloma Drugs Market Scope

Report Coverage

Details

Page number

167

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 5.9%

Market growth 2023-2027

USD 6419.94 million

Market structure

Fragmented

YoY growth (%)

5.76

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 36%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of contents:

1 Executive Summary

  • 1.1 Market overview

2 Market Landscape

  • 2.1 Market ecosystem

3 Market Sizing

  • 3.1 Market definition

  • 3.2 Market segment analysis

  • 3.3 Market size 2022

  • 3.4 Market outlook: Forecast for 2022-2027

4 Historic Market Size

  • 4.1 Global multiple myeloma drugs market 2017 - 2021

  • 4.2 Therapy Segment Analysis 2017 - 2021

  • 4.3 Distribution Channel Segment Analysis 2017 - 2021

  • 4.4 Geography Segment Analysis 2017 - 2021

  • 4.5 Country Segment Analysis 2017 - 2021

5 Five Forces Analysis

  • 5.1 Five forces summary

  • 5.2 Bargaining power of buyers

  • 5.3 Bargaining power of suppliers

  • 5.4 Threat of new entrants

  • 5.5 Threat of substitutes

  • 5.6 Threat of rivalry

  • 5.7 Market condition

6 Market Segmentation by Therapy

  • 6.1 Market segments

  • 6.2 Comparison by Therapy

  • 6.3 Targeted therapy - Market size and forecast 2022-2027

  • 6.4 Biologic therapy - Market size and forecast 2022-2027

  • 6.5 Chemotherapy - Market size and forecast 2022-2027

  • 6.6 Others - Market size and forecast 2022-2027

  • 6.7 Market opportunity by Therapy

7 Market Segmentation by Distribution Channel

  • 7.1 Market segments

  • 7.2 Comparison by Distribution Channel

  • 7.3 Hospital pharmacy - Market size and forecast 2022-2027

  • 7.4 Retail pharmacy - Market size and forecast 2022-2027

  • 7.5 E-pharmacy - Market size and forecast 2022-2027

  • 7.6 Market opportunity by Distribution Channel

8 Customer Landscape

  • 8.1 Customer landscape overview

9 Geographic Landscape

  • 9.1 Geographic segmentation

  • 9.2 Geographic comparison

  • 9.3 North America - Market size and forecast 2022-2027

  • 9.4 Europe - Market size and forecast 2022-2027

  • 9.5 Asia - Market size and forecast 2022-2027

  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027

  • 9.7 US - Market size and forecast 2022-2027

  • 9.8 Germany - Market size and forecast 2022-2027

  • 9.9 China - Market size and forecast 2022-2027

  • 9.10 Canada - Market size and forecast 2022-2027

  • 9.11 UK - Market size and forecast 2022-2027

  • 9.12 Market opportunity by geography

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers

  • 10.2 Market challenges

  • 10.3 Impact of drivers and challenges

  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview

  • 11.2 Vendor landscape

  • 11.3 Landscape disruption

  • 11.4 Industry risks

12 Vendor Analysis

  • 12.1 Vendors covered

  • 12.2 Market positioning of vendors

  • 12.3 Abbott Laboratories

  • 12.4 AbbVie Inc.

  • 12.5 Amgen Inc.

  • 12.6 Bristol Myers Squibb Co.

  • 12.7 Daiichi Sankyo Co. Ltd.

  • 12.8 F. Hoffmann La Roche Ltd.

  • 12.9 GlaxoSmithKline Plc

  • 12.10 Johnson and Johnson

  • 12.11 Merck and Co. Inc.

  • 12.12 Novartis AG

  • 12.13 Pfizer Inc.

  • 12.14 PharmaMar SA

  • 12.15 Sanofi SA

  • 12.16 Takeda Pharmaceutical Co. Ltd.

  • 12.17 Teva Pharmaceutical Industries Ltd.

13 Appendix

  • 13.1 Scope of the report

  • 13.2 Inclusions and exclusions checklist

  • 13.3 Currency conversion rates for US$

  • 13.4 Research methodology

  • 13.5 List of abbreviations

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Global Multiple Myeloma Drugs Market 2023-2027
Global Multiple Myeloma Drugs Market 2023-2027
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/multiple-myeloma-drugs-market-growth-opportunities-led-by-abbott-laboratories-and-abbvie-inc---technavio-301687186.html

SOURCE Technavio

Latest Stories

  • Why have there been no named winter storms this year?

    The UK hasn't seen a single named storm so far this autumn and winter. But why?

  • Troubling history of Malaga Island takes on added significance a century later

    Feb. 2—It's a story that must continue to be told. Though it's been more than a century since Maine forcibly removed all the residents of a mixed-race fishing community on Malaga Island off the coast of Phippsburg, the state's actions should never be forgotten, especially when racially motivated injustices continue to persist today, says a descendant of the community's patriarch. "It's ...

  • Nolly, review: fabulous, glamorous, joyous fun that makes Noele Gordon a star once more

    When Russell T Davies first approached ITV executives with the idea to make a drama about Noele Gordon, they replied: “Who’s he?” If you are under the age of 50, you might have the same response. But it doesn’t matter. In Nolly (ITVX), Davies gives us three hours of glorious high camp, which you will enjoy even if you have never heard of Crossroads.

  • Bed Frames Market Size & Revenue by 2029 | Latest Trends, Key Players, Types, Applications | Opportunities, Challenges, Risks Factors Analysis, Gross Margin and Revenue

    Pune, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Bed Frames Market report analysis benefits to shape the competition within the businesses and policies for the competitive environment to improve the possible revenue. The report evaluates key opportunities in the market and plans the factors that are and will drive the progress of the industry. Taking into account earlier growing patterns, growth drivers, and existing and upcoming trends, we also estimate the overall development of the global Bed Frames m

  • Trina Storage starts strong in 2023, signs over 100MWh Elementa deals in the UK

    Trina Storage, the vertically integrated battery energy storage solution provider, today announced the contract closure for another two Battery Energy Storage System (BESS) projects in the UK shortly after the signing of the 50MW/102 MWh Swangate project last month. These two new deals, 25MW/58MWh and 50MW/58MWh respectively, will also be utilizing Trina Storage's vertically integrated battery storage product – Elementa.

  • PSA Pet Owners: Shoppers Say 'You Need' This Robot Vacuum Mop Combo — and It's on Sale Right Now

    “This little vacuum packs a punch”

  • Olympic 100m Champion Marcell Jacobs Joins PUMA

    HERZOGENAURACH, Germany, February 02, 2023--PUMA has signed a long-term agreement with reigning Olympic 100 meters Champion Marcell Jacobs

  • 4me Powers Up Workflow Automation With Enterprise iPaaS Leader Workato

    4me Workflow Automator 4me Workflow Automator PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- In a move to better facilitate smooth workflow automation across enterprises and easy integration with third-party systems, enterprise service management platform 4me® has teamed up with leading iPaaS (Enterprise Integration Platform as a Service) vendor Workato to introduce the 4me Workflow Automator. Workato is an award-winning cloud automation and integration platform with enterprise-grade capab

  • ChatGPT May Already Be Used In Nation State Cyberattacks, Say IT Decision Makers in BlackBerry Global Research

    BlackBerry Limited (NYSE: BB; TSX: BB) today released new research revealing that half (51%) of IT professionals predict that we are less than a year away from a successful cyberattack being credited to ChatGPT, and 71% believe that foreign states may already be using the technology for malicious purposes against other nations.

  • Corona Sunsets Festival World Tour Makes Sunset the Headline Act

    Today, Corona, an AB InBev global brand, announced the 2023 Corona Sunsets Festival World Tour, a series of experiential festivals dedicated to connecting people with nature by celebrating the sunset. The festivals will feature experiences inspired by the magical qualities of the sunset.

  • ‘Your training literally saved our lives’: the British soldier teaching Ukrainians how to fight

    At a secret base outside the city of Kharkiv, ex-British soldier Daniel Ridley and his team drill hundreds of Ukrainian troops each week in the finer points of warfare.

  • Prime Enters Denmark with 124-Megawatt Data Center Campus That Delivers a Net-Positive Environmental Impact

    Prime, a global provider of hyperscale and wholesale data centers, today announced plans to expand its EMEA footprint to Denmark with a 124-megawatt campus. Located at Energivej in Saeby, Prime Denmark features three hyperscale data centers and will be marketed to international cloud providers, Internet businesses, AI, and the Global Fortune 500.

  • Share Buyback Transaction Details January 26 – February 1, 2023

    Share Buyback Transaction Details January 26 – February 1, 2023 February 2, 2023 - Wolters Kluwer (Euronext: WKL), a global leading provider of expert solutions, insights and services for professionals, today reports that it has repurchased 125,100 of its own ordinary shares in the period from January 26, 2023, up to and including February 1, 2023, for €12.4 million and at an average share price of €99.52. These repurchases are part of the share buyback program announced on November 2, 2022, und

  • Editorial: Bail reform becomes DeSantis’ latest work of deception

    Bail reform, or ending cash bail for people arrested on some or all charges, is not, from a statistical standpoint, a controversial topic. That’s why it has drawn strong bipartisan support in so many states and cities. It immediately reduces the cost burden on county jails. Combined with thoughtful pretrial supervision, including ankle monitors for some defendants, there’s no drop-off in the ...

  • Aurora Mobile Wins 2022 Excellent Digital Service Provider in China's SaaS Industry

    SHENZHEN, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it was recently recognized as the Excellent Digital Service Provider in China's SaaS Industry in the 2022 Sixth China Software and Information Service Industry Annual Billboard (the “Annual Billboard”). At the same time, the Company’s overseas messaging service platform

  • Invitation to presentation of Sinch’s year-end report for 2022

    Stockholm, Sweden – 2 February 2023 – Sinch AB (publ), a global leader in cloud communications and mobile customer engagement, will publish its year-end report for 2022 on Thursday 16 February 2023, at 07:30 CET. A conference call and a webcast will take place at 14:00 CET the same day where Sinch’s interim CEO Johan Hedberg and CFO Roshan Saldanha will present the report. There will be a possibility to ask questions after the presentation. Time for publication of the interim report Thursday 16

  • Ulta Beauty Is a Winner in Good Times And Bad

    After outperforming in 2022, shares of the beauty retailer look set for another good year. A wide product mix helps, especially if the economy gets rocky.

  • AWS Grows in Germany as More Firms Go Cloud-Native

    FRANKFURT, Germany, February 02, 2023--The use of cloud-native solutions in Germany continues to rise, benefiting hyperscale cloud providers such as AWS, ISG says.

  • Rokmaster Extends Option Payment on Revel Ridge Project

    Rokmaster Resources Corp. (TSXV: RKR) (OTCQB: RKMSF) (FSE: 1RR1) ("Rokmaster" or "the Company") is pleased to announce that it entered into an amending agreement with Huakan International Mining Inc. ("Huakan") and Huakan's shareholders to extend the fourth option payment due on February 25, 2023 by 12 months to February 25, 2024, at which time a penalty of $400,000 will also be due as consideration for the extension.

  • Pyramid Analytics Expands Germany Team With Appointment of Martin McDonald as New VP for the DACH Region

    MUNICH & NEW YORK & TEL AVIV, Israel, February 02, 2023--Pyramid Analytics (Pyramid), a pioneering business analytics and decision intelligence provider, has appointed Martin McDonald as Vice President DACH. McDonald has held various management positions in global technology companies looking to enter the German (DACH) market, including FredHopper and CoreMetrics. He most recently was VP DACHEE, Southern Europe at customer data specialist Tealium.